Table 4.

PAH studies including (more than 10) patients in FC II

Author/study	Year	Treatment	Design	Endpoint	Effect	No. FC II	Treat	FC II analysis
Galiè SUPER-142	2005	sildenafil	DB R P	6MWD	+42 m p < 0.001	108 of 278	75*	+40 m
Galiè43	2005	ambrisentan	DB R P	6MWD	+36 m p < 0.0001	23 of 64	17	+58 m
Galie EARLY36	2008	bosentan	DB R P	PVR	−197 p < 0.0001	185 of 185	93	n/a
				6MWD	+19 m ns			n/a
Galiè ARIES44	2008	ambrisentan	DB R P	6MWD	+43 m	165 of 383	113*	36–55 m
Simonneau UT1545	2002	trepostinil	DB R P	6MWD	+10 m	53 of 470	25	No
Galiè ALPHABET46	2002	beraprost	DB R P	6MWD	+15 m	64 of 130	31	No
Barst47	2003	beraprost	DB R P	VO2 max	p < 0.002	61 of 116	33	No
Barst STRIDE-148	2003	sitaxentan	DB R P	VO2 max	+1.1	59 of 178	37	No
Sastry49	2004	sildenafil	DB X P	Treadmill test	+211s p < 0.0001	18 of 22	18	No
Barst STRIDE-232	2006	sitaxentan	DB R P	6MWD	+28 m p < 0.05	92 of 185	47	No
		bosentan		6MWD	+29 m p < 0.05		22	No
Simonneau PACES50	2008	sildenafil	DB R P	6MWD	+29 m	71 of 267	35*	No

Notes: Treat column refers to the number of patients enrolled in each trial in FC I or II and assigned to treatment arm.

^*includes FC I patients.

Abbreviations: DB, double blind; R, randomized; P, placebo-controlled; X, crossover; 6MWD, six-minute walk distance; PVR, pulmonary vascular resistance; FC, functional class.